Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant.
Yun FanAndrew S ArtzKoen van BesienWendy StockRichard A LarsonOlatoyosi OdenikeLucy A GodleyJustin KlineJohn M CunninghamJames L LaBelleMichael R BishopHongtao LiuPublished in: Experimental hematology & oncology (2019)
In conclusion, second HCT is a viable option for disease relapse after TCD HCT for patients entering second HCT in remission and/or remission duration > 12 months after first HCT with acceptable rates of GVHD and donor engraftment.
Keyphrases
- disease activity
- stem cells
- ulcerative colitis
- cell cycle arrest
- end stage renal disease
- newly diagnosed
- ejection fraction
- stem cell transplantation
- rheumatoid arthritis
- systemic lupus erythematosus
- bone marrow
- chronic kidney disease
- prognostic factors
- free survival
- peritoneal dialysis
- hematopoietic stem cell
- low dose
- acute lymphoblastic leukemia